Liraglutide: A new treatment for type 2 diabetes
The DOI matches its Crossref record.
Abstract
Liraglutide is a novel glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence identity to native GLP-1. An amino acid substitution and fatty acid side chain enable a more protracted pharmacokinetic profile of over 24 hours. These modifications make liraglutide suitable for once-daily dosing. Liraglutide use exploits the incretin effect to glucose-dependently stimulate insulin secretion. The LEAD (Liraglutide Effect and Action Diabetes) program evaluated the safety and efficacy of liraglutide and demonstrated an improved level of glycemic control relative to currently used oral antidiabetic drugs, including other GLP-1-based therapies. In these trials, liraglutide was shown to enable many patients to achieve hemoglobin A1c (HbA1c) targets and to improve several morbidities commonly associated with type 2 diabetes; liraglutide induced weight loss, reduced systolic blood pressure and improved beta-cell function. Liraglutide was well tolerated, although an increased incidence of mild nausea was observed. Since liraglutide mimics the glucose-sensitive action of native GLP-1, it does not induce hypoglycemia. Liraglutide offers an interesting alternative therapy to control blood glucose levels in patients with type 2 diabetes, who commonly present with hypertension and overweight. It is expected to be approved by the U.S. Food and Drug Administration and the European Medicines Agency in Europe for use in 2009.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193
Sharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
“The results demonstrate that liraglutide, a drug that is on the market as a treatment for type 2 diabetes (Victoza ) (Vilsboll 2009), has neuroprotective properties in human neuroblastoma SH-SY5Y cells.”
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
“The weight loss was accompanied by a more pronounced loss in visceral fat than subcutaneous fat.([66,72,73]) Systolic blood pressure is also lowered by 2–6mmHg with liraglutide, independently from weight loss, as the reduction of blood pressure is observed early on in therapy, when weight loss has not yet occurred.”
InfluentialThe evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Zeng, S.-S., Bai, J.-J., Jiang, H., Zhu, J.-J., Fu, C.-C., He, M.-Z., Zhu, J.-H., Chen, S.-Q., Li, P.-J., Fu, X.-Q., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00585 · Cited by 35
Kong, Q.-X., Ruan, Q., Fan, C., Liu, B.-L., Reng, L.-P., & Xu, W. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0031 · Cited by 22
“GLP1-ras have a significantly extended GLP-1 half-life because they are not recognized by DPP-4 enzyme.”
BackgroundInfluential
Metadata
- Authors
- Vilsboll, T.
- Venue
- Drugs of Today
- Publisher
- Portico
- Published
- 2009
- Volume
- 45
- Issue
- 2
- Pages
- 101
- ISSN
- 0025-7656 (ISSN-L)
- 1699-4019
- OpenAlex
- W2124122508
- Cited by
- 50
- References
- 0
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.